We have previously reported bicyclic furanopyrimidines as potent and selective inhibitors of varicella zoster virus (VZV) with subnanomolar activity for p-alkylphenyl substituted analogues. These compounds are highly lipophilic and of limited water solubility. In an effort to address this issue, and with a view to oral dosing, we have sought to enhance water solubility whilst retaining high antiviral potency and we herein report a novel series of p-alkyloxyphenyl compounds which contain a phenolic ether atom intended to boost hydrophilicity. We report the synthesis, characterisation and antiviral evaluation of this series and note the retention of extremely high antiviral potency, with EC50 values as low as 1 nanomolar.
In 1999 we reported for the first time the potent anti-varicella zoster virus (VZV) activity of novel alkyl furano pyrimidines (1, Figure 1 ) (McGuigan et al., 1999) . EC 50 values as low as 10 nM were noted for compounds with an optimum side chain length of C8-C10 (1a-b). We noted an apparent correlation between antiviral potency and lipophilicity, with maximal potency at a calculated logP (ClogP) value of ca. 2.5-3.5 (C8-C10). Indeed, we subsequently noted that side chain modifications were tolerated provided they did not impinge significantly on the logP value. Thus, terminal halogens were tolerated (Brancale et al., 2000a) whilst a terminal hydroxyl group was not . Similarly, terminal alkenes were in general active whilst (more polar) alkynes were less active .
Our most successful modification to date is the p-alkylphenyl group (McGuigan et al., 2000) . Compounds of this type (2, Figure 1 ) showed EC 50 values as low as 0.1-0.5 nM, with optimal chain lengths of C4-C6 (optimum ClogP 2.4-3.5). Thus the overall 'length' of optimal chain appears roughly constant from Series 1 and 2, as does the apparent optimal lipophilicity.
One of the possible drawbacks of such unusually high lipophilicity is a rather poor water solubility; <<1mg/l for 1b for example (Brancale et al., 2000b) . Since this may complicate oral dosing of these agents we sought to enhance water solubility by the inclusion of a single ether, or glycol, unit into the alkyl side chain of 1 (Brancale et al., 2000b) . Indeed such compounds were noted to be significantly (>100-fold) more water soluble than the parent alkyl systems. However, the ether and glycol units had a significant impact on logP and in consequence, these compounds had considerably reduced antiviral potency; ∼100to 1000-fold for the ethers, >10 000-fold for the glycols.
Thus, we sought an alternative modification in the structure which would allow an increase in water solubility whilst retaining high antiviral potency. We believed that this would involve seeking to maintain high logP values. We herein report the synthesis and evaluation of some alkyloxyphenyl analogues in this regard.
Material and methods: chemistry
Thin layer chromatography (TLC)-commercially available Merck Kieselgel 60F 254 plates were used and were developed by the ascending method. After solvent evaporation, compounds were detected at 254 and 366 nm on irradiation with a UV lamp.
Column chromatography -glass columns were slurry packed in the appropriate eluent under gravity, with Woelm silica (32-63 mm). Samples were applied as a concentrated solution in the same eluent or pre-adsorbed onto silica gel. Fractions containing the product were identified by TLC, pooled and the solvent removed in vacuo.
NMR Spectroscopy: 1 H and 13 C NMR spectra were recorded on a Bruker Avance DPX300 spectrometer (300 and 75 MHz, respectively) and auto calibrated to the deuterated solvent reference peak. All 13 C NMR were proton decoupled. The following abbreviations are used in the assignment of NMR signals; s (singlet), d (doublet), t (triplet), m (multiplet), bs (broad signal), dd (double of doublets), dt (double of triplets).
Mass Spectrometry -low resolution mass spectra were obtained from a Fisons VG Platform II Fisons instrument (Fisons, Altrincham, UK) (atmospheric pressure ionisation, electrospray mass spectrometry) in either negative or positive ion mode. High resolution mass spectrometry was performed as a service by Birmingham University, using fast atom bombardment (FAB).
Standard procedure A: preparation of 5-alkynyl nucleosides 5-iodo-2′-deoxyuridine (1.0 mol. equiv.) was dissolved in dry DMF (∼10 ml) and stirred at room temperature under N 2 . Dry diisopropylethylamine (2.0 mol. equiv.), the appropriate alkyne (3-3.5 mol. equiv.), tetrakis (triphenylphosphine) palladium (0) (0.1 mol. equiv.) and copper (I) iodide (0.2 mol. equiv.) were added, and the reaction mixture was stirred at room temperature overnight under N 2 . The solvent was removed under reduced pressure and the remaining residue was redissolved in DCM:MeOH (1:1, ∼20 ml). An excess of amberlite IRA-400 (HCO 3 form) was added and the suspension was stirred for at least 30 min. The reaction mixture was filtered, washed with methanol and the solvent was removed under reduced pressure to leave the crude residue, which was purified by column chromatography and/or recrystallisation from suitable solvents.
Standard procedure B: cyclisation of 5-alkynyl nucleosides
To the relevant 5-alkynyl nucleoside, triethylamine (∼10 ml), methanol (∼10 ml) and copper (I) iodide (0.2 mol. equiv.) were added, and the mixture was heated under reflux for 4-5 h. The solvent was removed under reduced pressure to leave the crude residue which was purified by column chromatography using ethyl acetate initially and increasing the polarity to ethyl acetate/methanol (9:1).
Standard procedure C: one-pot procedure for the preparation of 2, 3-dihydrofuro [2, 3-d] pyrimidin-2-one nucleosides 5-iodo-2′-deoxyuridine (1.0 mol. equiv.) was dissolved in dry DMF (∼10 ml) and stirred at room temperature under N 2 . Dry diisopropylethylamine (2.0 mol. equiv.), the appropriate alkyne (3-3.5 mol. equiv.), tetrakis (triphenylphosphine) palladium (0) (0.1 mol. equiv.) and copper (I) iodide (0.2 mol. equiv.) were added and the reaction mixture was stirred at room temperature overnight under N 2 . Triethylamine (∼10 ml), methanol (∼10 ml) and copper (I) iodide (0.2 mol. equiv.) were added and the mixture was heated under reflux for 4-5 hours. The solvent was removed under reduced pressure and the remaining residue was redissolved in DCM:MeOH (1:1, ∼20 ml). An excess of amberlite IRA-400 (HCO 3 form) was added and the suspension was stirred for 30 min. The reaction mixture was filtered, washed with methanol and the solvent was removed under reduced pressure to leave the crude residue, which was purified by column chromatography using ethyl acetate initially and increasing the polarity to ethyl acetate/methanol (9:1).
5-(4-methoxy phenylethynyl)-2′-deoxyuridine (3a)
Prepared according to standard procedure A, 5-iodo-2′deoxyuridine (800 mg, 2.3 mmol) was dissolved in DMF (10 ml) and diisopropylethylamine (0.8 ml, 4.5 mmol), 4-methoxyphenylacetylene (912 mg, 6.9 mmol), tetrakis (triphenylphosphine) palladium (0) (261 mg, 0.23 mmol) and copper (I) iodide (86 mg, 0.45 mmol) were added and the reaction mixture was stirred at room temperature overnight under N 2 . The solvent was removed under reduced pressure and the remaining residue was redissolved in DCM:MeOH (1:1, 20 ml). An excess of amberlite IRA-400 (HCO 3 form) was added and the suspension was stirred for at least 30 min. The reaction mixture was filtered, washed with methanol and the solvent was removed under reduced pressure to leave the crude residue which was purified by column chromatography using EtOAc and increasing the solvent polarity to 10% MeOH:EtOAc (725 mg, 58% 
5-(4-ethoxy phenylethynyl)-2′-deoxyuridine (3b)
Prepared according to standard procedure A, 5-iodo-2′deoxyuridine (800 mg, 2.3 mmol) was dissolved in DMF (∼10 ml) and diisopropylethylamine (0.8 ml, 4.5 mmol), 4-ethoxyphenylacetylene (1008 mg, 6.9 mmol), tetrakis (triphenylphosphine) palladium (0) (261 mg, 0.23 mmol) and copper (I) iodide (86 mg, 0.45 mmol) were added and the reaction mixture was stirred at room temperature overnight under N 2 . The solvent was removed under reduced pressure and the remaining residue was redissolved in DCM:MeOH (1:1, ∼20 ml). An excess of amberlite IRA-400 (HCO 3 form) was added and the suspension was stirred for at least 30 min. The reaction mixture was filtered, washed with methanol and the solvent was removed under reduced pressure to leave the crude residue which was purified by column chromatography using EtOAc and increasing the solvent polarity to 10% MeOH:EtOAc (195 mg, 23%). 1 H NMR (d 6 -DMSO; 300 MHz); 11.80 (1H, s, NH), 8.34 (1H, s, H6), 7.42 (2H, H a )-6.94 (2H, H b ) (AB system, 1 J=7.8 Hz, 4 J=2.3 Hz), 6.17 (1H, t, J=6.2, H1′), 5.30 (1H, d, J=4.1 Hz, 3′OH), 5.20 (1H, t, J=5.1 Hz, 5′OH), 4.28 (1H, m, H4′), 4.09 (2H, q, J=7.1 Hz, OCH 2 ), 3.82 (1H, m, H3′), 3.66 (2H, m, H5′), 2.19 and 2.14 (2H, m, 2H′a and 2H′b), 1.36 (3H, t, J=7.0 Hz, CH 3 ). 13 C NMR (d 6 -DMSO; 75 MHz): 14.9 (CH 3 ), 40.7 (C2′), 61.2 (OCH 2 ), 63.6 (C5′), 70.4 (C3′), 81.1, 85.1 (C1′, C4′), 87.9 (-C≡C-Ph), 92.2 (-C≡C-Ph), 98.9 (C5), 115.1 (ipsoC), 133.1 (C4), 143.7 (CHb), 149.8 (CHa), 159.1 (paraC), 160.1 (C6), 161.9 (C2). MS (ES + ) m/e 395.2 (MNa + , 100%), 279.1 (baseNa + , 16%). Accurate mass: C 19 H 20 N 2 O 6 Na requires: 395.1219; found: 395.1226. Found: C, 59.92%; H, 5.65%; N, 7.39%. C 19 H 20 N 2 O 6 • 0.5H 2 O requires: C, 59.84%; H, 5.55%, N, 7.34%.
5-(4-propoxy phenylethynyl)-2′-deoxyuridine (3c)
Prepared according to standard procedure A, 5-iodo-2′deoxyuridine (1.2 g, 3.45 mmol) was dissolved in DMF (15 ml) and diisopropylethylamine (1.2 ml, 6.75 mmol), 4-propoxyphenylacetylene (1.658 g, 10.35 mmol), tetrakis (triphenylphosphine) palladium (0) (392 mg, 0.35 mmol) and copper (I) iodide (129 mg, 0.68 mmol) were added and the reaction mixture was stirred at room temperature overnight under N 2 . The solvent was removed under reduced pressure and the remaining residue was redissolved in DCM:MeOH (1:1, 20 ml). An excess of amberlite IRA-400 (HCO 3 form) was added and the suspension was stirred for at least 30 min. The reaction mixture was filtered, washed with methanol and the solvent was removed under reduced pressure to leave the crude residue which was purified by column chromatography using EtOAc and increasing the solvent polarity to 10% MeOH:EtOAc (659 mg, 49%). 1 
5-(4-hexoxy phenylethynyl)-2′-deoxyuridine (3e)
Prepared according to standard procedure A, 5-iodo-2′deoxyuridine (800 mg, 2.3 mmol) was dissolved in DMF (10 ml) and diisopropylethylamine (0.8 ml, 4.5 mmol), 4-hexoxyphenylacetylene (1.394 g, 6.9 mmol), tetrakis (triphenylphosphine) palladium (0) (261 mg, 0.23 mmol) and copper (I) iodide (86 mg, 0.45 mmol) were added and the reaction mixture was stirred at room temperature overnight under N 2 . The solvent was removed under reduced pressure and the remaining residue was redissolved in DCM:MeOH (1:1, 20 ml). An excess of amberlite IRA-400 (HCO 3 form) was added and the suspension was stirred for 30 min. The reaction mixture was filtered, washed with methanol and the solvent was removed under reduced pressure to leave the crude residue which was purified by column chromatography using EtOAc and increasing the solvent polarity to 10% MeOH:EtOAC (344 mg, 35% 
5-(4-heptoxy phenylethynyl)-2′-deoxyuridine (3f)
Prepared according to standard procedure A, 5-iodo-2′deoxyuridine (800 mg, 2.3 mmol) was dissolved in DMF (∼10 ml) and diisopropylethylamine (0.8 ml, 4.5 mmol), 4-heptoxyphenylacetylene (1.49 g, 6.9 mmol), tetrakis (triphenylphosphine) palladium (0) (261 mg, 0.23 mmol) and copper (I) iodide (86 mg, 0.45 mmol) were added and the reaction mixture was stirred at room temperature overnight under N 2 . The solvent was removed under reduced pressure and the remaining residue was redissolved in DCM:MeOH (1:1, ∼20 ml). An excess of amberlite IRA-400 (HCO 3 form) was added and the suspension was stirred for 30 min. The reaction mixture was filtered, washed with methanol and the solvent was removed under reduced pressure to leave the crude residue which was purified by column chromatography using EtOAc and increasing the solvent polarity to 10% MeOH:EtOAc (604 mg, 59%). 1 H NMR (d 6 -DMSO; 300 MHz); 11.76 (1H, s, NH), 8.34 (1H, s, H6), 7.41 (2H, H a )-6.96 (2H, H b ) (AB system, 3 J=7.9 Hz, 4 J=2.3 Hz), 6.17 (1H, t, J=6.2 Hz, H1′), 5.30 (1H, d, J=4.1 Hz, 3′ OH), 5.19 (1H, t, J=5.1 Hz, 5′ OH), 4.27 (1H, m, H4′), 3.97 (2H, q, J=7.1 Hz, OCH 2 ), 3.82 (1H, m, H3′), 3.68 (2H, m, H5′), 2.19 and 2.14 (2H, m, 2H′a and 2H′b), 1.33 (2H, m, CH 2 ), 1.27 (8H, m, 4×CH 2 ), 0.86 (3H, t, J=7.0 Hz, CH 3 ). 13 
3-
This compound was prepared according to standard procedure B using compound (3b) (150 mg, 0.403 mmol), which gave 3-(2′-deoxy-β-D-ribofuranosyl)-6-(4-n-chlorophenylacetylene)-2, 3-dihydrofuro-[2, 3-d] pyrimidin-2-one (256 mg, 30%), after purification by column chromatography. 1 
3-(2′-deoxy
The procedure was carried out using 4-n-propoxyphenylacetylene (1.08 g, 6.76 mmol), which gave 3-(2′-deoxy-β-D-ribofuranosyl)-6-(4-n-propoxyphenylacetylene)-2, 3dihydrofuro-[2, 3-d] pyrimidin-2-one (552 mg, 59%), after purification by column chromatography. 1 
The procedure was carried out using standard procedure C using 4-n-pentoxyphenylacetylene (1.27 g, 6.76 mmol), which gave 3-(2′-deoxy-β-D-ribofuranosyl)-6-(4-n-pentoxyphenylacetylene)-2, 3-dihydrofuro-[2, 3-d] pyrimidin-2-one (503 mg, 53%), after purification by column chromatography. 1 4, 25.8, 28.8, 31.6, 33.7 (CH 2 ), 41.6 (C2′), 61.2 (C5′), 68.8 (OCH 2 ), 69.8 (C3′), 88.1, 88.7 (C1′, C4′), 99.7 (C5), 107.0 (C4a), 115.3 (CHb), 121.1 (ipsoC), 126.8 (CHa), 137.5 (C4), 154.2 (paraC), 154.5 (C6), 161.2 (C2), 171.8 (C7a). MS (ES + ) m/e 465 (MNa + , 100%), 349 (baseNa + , 10%). Accurate mass: C 24 H 30 N 2 O 6 Na requires: 465.2002; found: 465.2001 . Found: C, 62.74%; H, 7.08%; N, 6.06%. C 24 H 30 N 2 O 6 •H 2 O requires: C, 62.59%; H, 7.01%, N, 6.08%.
Lipophilicity calculation.
Lipophilicity values (ClogP) were calculated using ClogP 1.0.0 (BioByte, Claremont, California) as previously noted .
Water solubility
A water solubility study was carried out using a Helios Alpha UV-visible spectrometer (Unicam Ltd, Cambridge, UK). The extinction coefficient of a 5.0×10 -5 M solution of 4a in water at room temperature was calculated (λ max 291 nm), and the resulting ε value (18835 l mol -1 cm -1 ) was then used to calculate the aqueous solubility of the other furano pyrimidines, using saturated solutions in water filtered through 0.22 µm Millipore filters.
Materials and methods: virology

Cells
Human embryonic lung (HEL) fibroblasts and E6SM cells were grown in minimum essential medium (MEM) supplemented with 10% inactivated fetal calf serum (FCS), 2mM L-glutamine and 0.3% sodium bicarbonate.
Viruses
The laboratory wild-type VZV strains OKA and YS, the thymidine kinase-deficient VZV strains 07-1 and YS-R, herpes simplex virus type 1 (HSV-1) (KOS), herpes simplex virus type 2 HSV-2 (G), the thymidine kinase-deficient HSV-1 strains B-2006 and VMW 1837, cytomegalovirus strains Davis and AD-169, and vaccinia virus (VV) were used in the virus inhibition assays.
Antiviral assays
Confluent HEL cells grown in 96-well microtitre plates were inoculated with VZV at an input of 20 plaque forming units (PFU) per well or with cytomegalovirus (CMV) at an input of 100 PFU per well or with HSV at 100 CCID 50 (50% cell culture infective doses) per well. After a 1 to 2-h incubation period, residual virus was removed, and the infected cells were further incubated with MEM (supplemented with 2% inactivated FCS, 2 mM L-glutamine and 0.3% sodium bicarbonate) containing varying concentrations of the compounds. Antiviral activity was expressed as EC 50 (50% effective concentration), or compound concentration required to reduce viral plaque formation after 5 days (VZV) or virus-induced cytopathicity (CMV after 7 days or HSV, VV after 3 days) by 50% compared to the untreated control.
Cytotoxicity assays
Confluent monolayers of HEL cells as well as growing HEL cells in 96-well microtiter plates were treated with different concentrations of the experimental drugs. Cell cultures were incubated for 3 (growing cells) or 5 (confluent cells) days. At the indicated times, the cells were trypsinized and the cell number was determined using a Coulter counter. The 50% cytostatic concentration (CC 50 ) was defined as the compound concentration required to reduce the cell number by 50%.
Results
Chemistry
The synthetic route used in the present case follows entirely that we have reported for the parent p-alkylphenyl system (McGuigan et al., 2000) .
Thus, 5-iodo-2′-deoxyuridine (IDU) was the key starting material, which was allowed to react with a series of p-alkyloxyphenyl acetylenes (Scheme 1) under Pd(0) and Cu(1) catalysis. This gave intermediate 5-alkynyl deoxyuridines (3a-f) with alkyloxy chain lengths from C1 (3a) to C7 (3f). These compounds were then smoothly converted to the desired furano pyrimidines 4a-f by copper catalysis (Scheme 1).
Intermediates (3a-f) and final products (4a-f) were all fully characterised by proton-and carbon-NMR, mass spectrometry and microanalysis. Yields were 23-59% for the first step and 11-29% for the second step (unoptimised). In the case of 4d the product was isolated in good yield from IDU in one pot, without the isolation of 3d.
As we have previously noted an apparent correlation between lipophilicity and antiviral potency , we calculated the logP values of 4a-f and these are given in Table 1 (McGuigan et al., 2000 for reference data).
Antiviral activity
The target bicyclic systems 4a-f were evaluated for their ability to inhibit the replication of VZV according to previously described methods (De Clercq et al., 1986) . Data are shown in Table 1 for the activity of 4a-f versus two strains of thymidine kinase-competent (TK + ) VZV and also two strains of thymidine kinase deficient (TK -) VZV with data also included for the reference anti-herpetics acyclovir (5) and BVDU (6) (De Clercq et al., 1979) ( Figure 2 ). We also include data for the representative phenyl systems (2a-d).
Discussion
From the data in the Table it is notable that the alkyloxyphenyl compounds 4a-f retain a potent and selective anti-VZV activity that is almost entirely VZV TK dependent. This follows entirely the pattern of the parent p-alkylphenyl systems (McGuigan et al. 2000) . Furthermore, we note the same apparent correlation between antiviral potency and lipophilicity, with an optimal ClogP of ∼2.5, and an optimal side chain of pentyloxy (4d). The lead compound 4d is noted to be ∼3000-times more potent than the leading anti-herpetic acyclovir (5) and slightly (threefold) more potent than BVDU (6). The lead compound is 3-to 10-fold less potent than the pentylphenyl compound 2c. However, the lack of cytotoxicity for 4d still confers an extremely high SI value (>200 000).
Since one of the main purposes for preparing this new series was to enhance water solubility whilst retaining lipophilicity and antiviral potency, we were interested to carry out an initial water solubility study. Thus, compounds 4a, 4c and 4e were studied, alongside parent alkylphenyl analogues 2a-d and the alkyl parent 1a, with data being shown in Table 2 . Compound 1a was so water insoluble that no UV spectrum could be recorded in water, thus placing a very low upper limit on the water solubility. The short chain alkyl phenyl compounds 2a-b were detectable, and using the same extinction coefficient as recorded for 4a, water solubility values of ∼9.4 and 0.2 mg/l were recorded for 2a-b, respectively. However, the longer chain alkylphenyl compounds 2c-d were again not detectable by UV, and only upper limits of solubility can be given. The rapidly diminishing water solubility with alkyl chain length is clear for 2a-d; indeed it is notable that solubility falls almost in proportion to increasing ClogP (Figure 3) .
It is gratifying to see that the alkyloxy phenyl systems show improved water solubilities, comparing similar systems, whilst retaining high ClogPs (and therefore high antiviral activity). For example, the methoxy system (4a) has a ClogP (0.27) almost the same as that of the methylphenyl compound (2a) (0.8), but the former has a 2.5-fold solubility enhancement. Similarly, the propyloxy compound (4c) is 26-fold more water soluble than the p-propyl analogue (2b), whilst retaining full antiviral potency. Indeed, even the longest chain alkyloxyphenyl compound studied (4e) has a detectable, albeit small, water solubility, whilst the alkylphenyl compound with virtually the same ClogP (2c), and the parent alkyl with a lower ClogP (1a) are both undetectable. For each value of ClogP it is apparent that the alkyloxy phenyl series offers enhanced water solubility (Figure 3 ). For a more thorough pursuit of this area it may well be desirable to measure, rather than calculate, logP values, although this may be troublesome for the highly lipophilic compounds herein reported. Furthermore, the ClogP package used reports all fragments to be measured for these compounds, and we anticipate a reasonable level of confidence in these values, particularly in the comparative rather than absolute terms that values are herein discussed.
Finally, the target bicyclic systems 4a-f were evaluated for their ability to inhibit the replication of human CMV, VV and HSV-1 and -2 according to previously described methods (De Clercq et al., 1986) . None of the compounds displayed any antiviral activity at non-toxic concentrations, indicating them to be entirely specific to VZV in their antiviral effect, as previoulsy noted by us for compounds of this class (McGuigan et al., 2000) .
Conclusion
We have reported the design, synthesis and evaluation of a series of p-alkyloxyphenyl bicyclic furanopyrimidines as potent and selective inhibitors of VZV. We were particularly keen to enhance water solubility whilst retaining high ClogP values, a parameter that had previoulsy been seen to correlate with high antiviral potency. To an extent this was achieved; thus the propyloxy compound (4c) is 26-fold more water soluble than the p-propyl analogue (2b), whilst retaining full antiviral potency.
Thus, in contrast to the earlier reported ether and glycol-based alkyl furanopyrimidines, where solubility enhancements were only achieved to the detriment of potency, in the aryloxy series herein reported we have achieved significant solubility boosts without compromising antiviral efficacy. By consideration of the aryl ethers, significant boosts in water solubility are thus possible with only minor reductions in logP values, thus retaining antiviral potency. 
